Key Takeaways
- Strong revenue growth, custom synthesis shift: Significant Q2 revenue growth was driven by expanding custom synthesis opportunities, with demand rising from both existing and new customers.
- Generic pricing pressure persists, volume holds: Industry-wide pricing pressure across all segments suppressed sales, but volume-based growth kept the generic business at 49% of revenue.
- Unit-III greenfield on track for December: The 200-acre Kakinada project will begin phase-wise production in December 2024, starting with one block.
- Peptide infrastructure built for custom synthesis only: Solid Phase Peptide Synthesis (SPPS) facilities are operational and expanding, but the GLP-1 business is strictly custom synthesis, not generic.
- What to watch next quarter: Whether Unit-III production begins on schedule, any sign of the hoped-for generic pricing stabilization, and progress on peptide fragment qualifications.
Generic Business: Pricing vs. Volume
- Pricing pressure is industry-wide: Pressure spans all segments and therapies, including Naproxen, Gabapentin, Carbidopa, and Levodopa, driven by global inflation and government agencies pushing for more affordable medicines, passed down from customers.
- Volume growth offsets the hit: Despite pricing headwinds, most generic products saw good volume-based growth, particularly key products where Divi's has leading market share; growth was double-digit.
- Market share gains continue: Smaller APIs are gaining market share, and the generic business sustained at 49% of revenue through volume growth across both large and smaller molecules.
- Stabilization is a hope, not a forecast: Management hopes to see at least some pricing stability in the next six months to a year, but acknowledges it is very hard to predict.
Nilima Prasad Divi: "It is very hard to answer that particular question, but that is the hope that in the next six months to a year, we should see at least some stability with respect to the pricing pressure."
Custom Synthesis & the Peptide Opportunity
- Custom synthesis landscape shifting: A significant shift is underway with increasing demand from existing and new customers; Divi's is focused on securing long-term partnerships that emphasize supply chain resilience and backward integration.
- Peptide infrastructure is real and growing: Dedicated Solid Phase Peptide Synthesis (SPPS) infrastructure is operational with multiple 500-litre reactors, and facilities are expanding further due to rising demand.
- GLP-1 strategy is strictly custom synthesis: Divi's manufactures fragments (octamers, decamers) based on customer requirements and is not producing generic APIs or building inventory; the company will only do what the customer requests, though it has end-to-end API capability if asked.
- Commercialization timeline depends on customers: Peptide fragments are undergoing qualifications; supply could start sooner than 12-15 months, but the timeline depends entirely on regulatory approvals in the US, Europe, and Japan.
Dr. Kiran S. Divi: "We are not looking at the generic side. So, we are not producing different octamers or different decamers or APIs and keeping it ready. We are strictly looking it as a CS business at this point."
Expansion Projects & Capex
- Unit-III (Kakinada) starting December 2024: The 200-acre greenfield project will begin phase-wise production with one block; Phase-I is expected to be fully utilized in the next six to seven months, initially doing backward integration while awaiting regulatory approvals.
- Continuous flow chemistry scaling up: Successfully utilized in labs and at pilot scale, with expansion into commercial-scale production set for the next one to two years.
- Capex trajectory: Capex is ongoing and will keep adding as custom synthesis projects are finalized; next year's capex is expected to be slightly lower as it will be brownfield expansion, unless a huge opportunity requires massive investment.
- Unit-III EBITDA breakeven: Management gave no specific timeline, stating it will take time to stabilize Phase-I.
Contrast Media & Future Generics
- Contrast media volume growing: Year-on-year volume increase of 20% to 30% is a fair statement; some Iodine-based products are already commercialized with long-term contracts.
- Gadolinium still in qualification: Gadolinium compounds remain in qualification stages with customers; management hopes to commercialize them in the next one to two years.
- Future generics pipeline: A robust pipeline of generic products is advancing toward customer qualifications and regulatory approvals in the US and Europe, with launches anticipated from 2026, some in 2027-28, and others all the way to 2029.
- Ticagrelor confirmed: Coming off patent in 2026 and Divi's is working on it; management declined to disclose other specific drug names.
Dr. Kiran S. Divi: "we have the six growth engines in place, right from our existing business generic products which we are maintaining them quite stable and then increasing it in growth in terms of volume, we also have our Sartan business, which is growing steadily. Our future generics, which are ready to be launched from 2026 and we are undergoing various stage of qualifications with our customers and we are gearing up a launch from 2026, some are going to be launched in '27-28 all the way to '29."
Supply Chain & Margin Levers
- Red Sea disruption managed proactively: Transit times extended from ~45 days to ~70 days, raising logistics costs; Divi's advanced shipments by 3-4 weeks, maintained extended safety stock levels, and diversified its supply base to minimize disruption.
- Raw material stability with caution: Raw material prices have been stable over the past six months and are showing a downward, stabilizing trend after rising in previous years; management expects stable material costs this year but remains cautious given Middle East sensitivity and crude oil fluctuations.
- Other expenses flat to slightly down YoY: Green chemistry implementation, efficiency improvements, and backward integration are containing costs; other expenses are expected to remain at approximately similar levels.
- Gross margin QoQ decline: Generic pricing pressure played a role, but management advises against quarter-on-quarter comparisons due to lumpiness in shipments and customer requirements, recommending a full-year view.
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Unit-III production start | Phase-wise production beginning with one block | December 2024 |
| Unit-III Phase-I full utilization | Backward integration initially while awaiting regulatory approvals | Next 6-7 months |
| Continuous flow chemistry commercial scale | Expand from pilot to commercial production | Next 1-2 years |
| Future generics launches | Pipeline advancing through customer qualifications and regulatory approvals | Starting 2026, through 2029 |
| Capex next year | Slightly lower than this year, brownfield expansion, barring a huge opportunity | FY26 |
Key Metrics
| Metric | Q2 FY25 |
|---|---|
| Consolidated total income | ₹2,444 cr, vs ₹1,995 cr YoY and ₹2,197 cr QoQ |
| Profit before tax | ₹722 cr, vs ₹469 cr YoY |
| Profit after tax | ₹510 cr, vs ₹348 cr YoY |
| Material consumption | ~41% of sales revenue for H1 FY25, vs 40% in Q1 FY25 |
| Constant currency growth (H1) | 21% |
| Exports share (H1) | ~87% of total sales revenue |
| Europe and US combined export share (H1) | ~71% of total sales revenue |
| Product mix: generics vs custom synthesis (H1) | 49% and 51% respectively |
| Nutraceutical business revenue (H1) | ₹406 cr |
| Forex gain (H1) | ₹28 cr, vs ₹14 cr YoY |
| Generic business volume growth | Double digit |
| Contrast media volume growth outlook | 20% to 30% year-on-year |
| CAPEX guidance for FY25 | ~₹1,600 cr (including Kakinada) |
| Capital work-in-progress | ₹1,316 cr as of Sep 30, 2024, of which Kakinada project accounts for ₹1,006 cr |
| Total spent on Kakinada project | ₹1,181 cr till Sep 30, 2024 |
| Cash on books | ₹3,602 cr as of Sep 30, 2024 |
| Receivables | ₹2,181 cr as of Sep 30, 2024 |
| Inventories | ₹3,145 cr as of Sep 30, 2024 |
| Transit times | ~70 days, extended from ~45 days due to Red Sea disruptions |